Qube Research & Technologies (QRT)
CCCC icon

Qube Research & Technologies (QRT)’s C4 Therapeutics CCCC Stock Holding History

Qube Research & Technologies (QRT)’s Portfolio CCCC Stock Details CCCC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.73M Sell
370,554
-381,560
-51% -$1.31M ﹤0.01% 2189
2026
Q1 		$1.98M Buy
752,114
+461,880
+159% +$1.09M ﹤0.01% 2184
2025
Q4 		$554K Buy
290,234
+174,261
+150% +$413K ﹤0.01% 2770
2025
Q3 		$257K Buy
+115,973
New +$278K ﹤0.01% 2887
2024
Q3 		– Sell
-258,426
Closed -$1.19M – 3384
2024
Q2 		$1.19M Sell
258,426
-129,767
-33% -$774K ﹤0.01% 1813
2024
Q1 		$3.17M Buy
388,193
+361,103
+1,333% +$2.8M 0.01% 1486
2023
Q4 		$153K Buy
27,090
+20,204
+293% +$46.1K ﹤0.01% 2935
2023
Q3 		$12.8K Sell
6,886
-69,896
-91% -$213K ﹤0.01% 3271
2023
Q2 		$211K Buy
76,782
+47,094
+159% +$151K ﹤0.01% 1761
2023
Q1 		$93.2K Buy
+29,688
New +$175K ﹤0.01% 2138

Other funds holding CCCC

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $322M AUM
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Qube Research & Technologies (QRT)'s CCCC Position: Q2 2026 in Review

Qube Research & Technologies (QRT) reduced its C4 Therapeutics (CCCC) stake by 51% in Q2 2026, selling an estimated $1.31M and leaving 370,554 shares worth $1.73M. The position accounts for ﹤0.01% of the portfolio, ranked #2189.

Qube Research & Technologies (QRT) first reported a position in CCCC in Q1 2023 and has held it in 10 quarters since. The position peaked at $3.17M in Q1 2024. 147 funds tracked by Wall St. Rank hold CCCC as of Q2 2026.

  • Qube Research & Technologies (QRT) held 370,554 shares of C4 Therapeutics worth $1.73M as of Q2 2026.
  • Qube Research & Technologies (QRT) sold 381,560 C4 Therapeutics shares in Q2 2026, an estimated $1.31M.
  • C4 Therapeutics made up ﹤0.01% of Qube Research & Technologies (QRT)'s portfolio in Q2 2026, its #2189 holding.
  • Qube Research & Technologies (QRT) first reported a position in C4 Therapeutics in Q1 2023 and has held it in 10 quarters since.
  • Qube Research & Technologies (QRT)'s C4 Therapeutics position peaked at $3.17M in Q1 2024.
  • 147 funds tracked by Wall St. Rank held C4 Therapeutics as of Q2 2026.

Based on Qube Research & Technologies (QRT)'s 13F filing for Q2 2026, filed 14 Aug 2026.